Breast Milk Kills Cancer Cells & HPV Warts

Human breast milk kills cancer cells.

It also cures skin warts. Skin warts are caused by the HPV virus, and some strains cause cervical cancer.


http://www.king5.com/health/stories/NW_051607WABbreastmilkKS.76d94c42.html

Cancer patients turn to breast milk for treatment


Professor Svanborg comments, "Treatment with Hamlet has a beneficial and lasting effect on skin papillomas (warts). This may have relevance for the treatment of cervical cancer, because virally infected and cancer cells are similar."

HAMLET, for Human Alpha-lactalbumin Made Lethal to Tumor cells... it would represent a great advance over the toxic cancer drugs currently in use with their high risk of negative side effects.


http://www.cbsnews.com/stories/2004/06/23/health/main625825.shtml
Breast Milk Kills Skin Warts
Researchers Take A Closer Look At Component Of Human Breast Milk


"… immunologist Catharina Svanborg and a team of research biologists at Sweden's Lund University discovered in breastmilk a protein compound, alpha-lactalbumin (they gave it the acronym HAMLET), that selectively induces apoptosis in tumor cells. (4) In other words, HAMLET makes cancer cells commit suicide. In fact, it has killed every type of cancer the researchers have tested it against. HAMLET has also been used to successfully treat virally infected warts, which were reduced by 75 percent in volunteers who received daily treatments with an ointment containing the protein. The same viruses that cause warts are also linked to cervical cancer, genital warts, and some types of skin cancer. Well, we all knew that breastmilk is powerful."

http://findarticles.com/p/articles/mi_m0838/is_133/ai_n15800369http://www.staffnurse.com/nursing-news-articles/breast-milk-compound-could-protect-against-cancer-687.html


Breast Milk Compound Could Protect Against Cancer

A compound in breast milk can destroy warts, researchers have discovered.The human papilloma virus, which causes warts, is a common virus and has similarities with the virus found in cervical cancer.

Professor Catharina Svanborg and colleagues of Lund University, Sweden, have named the breast milk compound Hamlet, short for 'human alpha-lactalbumin made lethal to tumour cells'.
They applied human breast-milk to warts and found that the virus was killed in 75 per cent of patients whose warts had resisted all other treatment.The discovery is published in the current issue of the New England Journal of Medicine.The scientists believe that the discovery could help treat cervical cancer, and plan to carry out a trial on women with cervical cancer. It may also be relevant to a range of other lethal diseases caused by the human papilloma virus, including, squamous cell skin cancer and dangerous throat lesions.

Professor Svanborg comments, "Treatment with Hamlet has a beneficial and lasting effect on skin papillomas (warts). This may have relevance for the treatment of cervical cancer, because virally infected and cancer cells are similar."Hamlet is able to selectively kill wart cells while leaving healthy tissue unharmed. Breast milk is already known to contain an antibiotic, but this effect on viruses was discovered by accident.N Engl J Med 2004; 350:2663-2672Date: June 28th 2004

The drug companies would probably make a synthetic drug that kills the cancer…” Svanborg said if HAMLET proves useful against serious diseases, the compound would probably be synthesized in the lab instead of being extracted from breast milk.”

http://www.sciencenews.org/articles/20061209/bob8.asp


Research teams are now learning to exploit its tricks for purposes well beyond feeding babies. Components of breast milk are being developed as drugs that fight viruses and bacteria. A particular target is diarrhea, which kills about 2.2 million people every year, mostly children in developing countries. Other milk compounds may be added to food to improve digestion. Some milk components might fight medical conditions ranging from arthritis to septic shock.

You may wonder why this discovery of a possible cure for cancer has not received greater attention. Funding is part of the problem, but slowly, in the past decade, more attention has been paid to this small laboratory in a quiet corner of the world. Even the American Cancer Society has given its stamp of approval by giving a grant to Svanborg and her team to help fund further research into their discovery. Mothering, Nov-Dec, 2005 by Liz Laing http://findarticles.com/p/articles/mi_m0838/is_133/ai_n15800369/pg_2


Researchers Deliberate Over Whether to Publish

http://ublib.buffalo.edu/libraries/projects/cases/milk/milk.html

The winter days had become too short. It always seemed like twilight in this country so close to the Arctic Circle. The sky remained grey even in the midday light. It was three o'clock, and the coffee break she had just taken had refreshed her somewhat. As she prepared to run the last samples of the day, she took her glasses off and rubbed her eyes, then rested her head in the palm of her cool hands for a few minutes. Somehow she just couldn't seem to shake the mid-December depression she was feeling. She could hear the students arguing in the laboratory next door. They seemed to be quite distracted from their usual afternoon daily lab meeting where the day's findings were discussed and plans were made for the next day's work. A sharp knock at her door jarred her into her formal posture reserved for colleagues and students.
"Dr. Svanborg?"

Maybe it was the new medication she was taking, but Catherine Svanborg just couldn't seem to focus. Or maybe it was the deadline coming up in two weeks for the NIH grant she was preparing. She would be spending Christmas alone again, as she gave way to the last-minute details involved in writing her yearly report of findings. Ever since joining Lund University as a research associate in 1990, she had been trying to build a reputation as a serious authority in immunology. Recognition in the form of a grant from a prestigious organization would place her in that category.

"Can this wait until tomorrow?" she asked.

The student replied that it couldn't wait -- that she might find what was going on in the next room very disturbing. The student was one of Dr. Svanborg's most promising researchers. He had been working on the effects of various protein extracts of human breast milk on virally infected tissue cultures and was making good progress toward isolating factors that activated the immune response toward the retrovirus.

"Dr. Svanborg! Really, you must come look at this tissue culture of cancer cells I've got under the fluorescent microscope. Something very weird is happening, and we can't agree on what it is!"

In the next few minutes he showed her something that would send shivers of excitement through her body -- like the time she received the letter announcing her election as a bona fide fellow to the Royal Academy of Science of Sweden.

Svanborg looked into the microscope. Did she actually see what she thought she was seeing? Another look confirmed that the cancer cells were indeed "committing suicide!" Without looking away, she drew a lab stool under her to steady her trembling knees. For the next half-hour, she stared into the scope, and yes, something was causing the cancer cells to "explode" from within!
The news her student had brought seemed completely unrelated to the topic he was actually researching. He had been looking for how mother's milk fights viruses in tissue culture. The virus is introduced into the cancer cells (or the culture) and treated with milk components to see if there is an increase of viral destruction. What he observed -- the cancer cells "committing suicide" -- wasn't typical because normally they reproduce forever without dying, a kind of cell-line immortality. That immortality makes cancer cells a good medium for tissue culture. Normal human cells commit suicide every day. The process of cellular suicide is called apoptosis. What the graduate student found was a protein factor in the milk that induced the cultured cells to die.


Drug companies are already making solutions and drugs out of it.

http://www.strictlyfinancing.com/media(27,1033)/NatImmune.pdf

HAMLET, for Human Alpha-lactalbumin Made Lethal to Tumor cells... it would represent a great advance over the toxic cancer drugs currently in use with their high risk of negative side effects.

In-house development projects of three drug candidates:BAMLET Topical Gelfor dermatological use in skin wart, genital warts, actinic keratosisBAMLET Solutionfor bladder cancerrHAMLET Solutionfor glioblastoma



http://www.natimmune.com/sider/main.htm

NatImmune A/S is a biotech company focusing on the development of protein-based therapeutics for the prevention and treatment of cancer and infectious diseases.We build on a sound scientific foundation, a experienced pharmaceutical development team, a strong intellectual property rights portfolio, and a focused pipeline of products under development.The lead product is based on replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the immune system. This projectis partnered with ENZON Pharmaceuticals, Inc.

Our in-house lead technology, HAMLET, a novel anti-cancer agent with clinical proof-of-concept in skin warts, is being developed as three different products target several indications in dermatology and cancer. The HAMLET technology has demonstrated shown induction of apoptosis in bladder cancer papillomas, as well as strong preclinical proof-of-concept in glioblastoma multiforme. A phase IIb clinical trial is starting Q1 2008.

An antibody project aimed at a disease-specific target found only in Colorectal Cancers (CRC) and other adenocarcinomas is in the preclinical phase.